Board of Directors


Kim Bjørnstrup
Chairman, independent

Mr. Bjørnstrup has been Chairman of the Board of Veloxis since April 2011. He has more than 20 years of working experience in the pharmaceutical industry. During the past 18 years, he has held various executive positions in the management team of the Octapharma Group and served 8 years as Vice Chairman. Prior to this, he has worked with Coloplast A/S and H. Lundbeck A/S.

As of 1. August 2013 Kim Bjørrnstrup has been appointed CEO of BPL Holdings Ltd. BPL Holding is an organization focused on manufacturing and selling Lifesaving drugs based on human plasma. The group employs 1800 people and is headquartered in Elstree outside London. Kim Bjørnstrup is trained as a lawyer and holds a Master of Law from Copenhagen University.

Special competencies, important for his capacity as a Board Member, comprise his extensive international biotechnology industry experience and network together with his extensive business development experience



Dr. Thomas Dyrberg
Deputy Chairman, independent

Dr. Dyrberg has been a Board Member of Veloxis since September 2003. Dr. Dyrberg, Senior Partner, has served at Novo Ventures, Novo A/S, a Danish firm that provides capital for life science companies, since December 2000.

Prior to joining Novo A/S, he served in various positions at Novo Nordisk A/S, a health care company specializing in the treatment of diabetes. Prior to that, he held research positions at the Hagedorn Research Institute, Gentofte, Denmark, and the Scripps Research Institute, La Jolla, California, US.

Dr. Dyrberg received both an MD and a DMSc degree from the University of Copenhagen.

Dr. Dyrberg is the Chairman of the Board of Directors of Lux Biosciences Inc. (US). He currently also serves on the Board of Directors of AlloCure Inc. (US), Delenex Therapeutics AG (Switzerland), Imagen Biotech Inc. (US), Ophthotech Corporation (US).

Special competencies, important for his capacity as a board member of Veloxis, comprise his extensive life-science experience and funding of biotechnological companies.

Mette Kirstine Agger
Board member, independent

Ms. Agger has been a Board Member of Veloxis since April 2010. Ms. Agger is an Executive Director and Head of LFI Life Science Investments A/S. She joined LFI A/S, a company fully owned by the Lundbeck Foundation, on 1 September 2009.

Prior to this, Ms. Agger was CEO of 7TM Pharma A/S, which she cofounded in late 2000, and from 1996 to 2000 she was part of the management team at NeuroSearch A/S, responsible for business development and licensing.

Ms. Agger is a member of the Board of Directors at Harboe Breweries A/S and Statens Serum Institute, and is Chairman of the Board of Directors of Klifo A/S. Ms. Agger has a Master of Science in Biology from Copenhagen University and an MBA from the Henley Business School, UK.

Ms. Agger's special competencies, which are important for her capacity as a board member, are her extensive biotechnology industry experience and network together with her extensive business development experience and knowledge of intellectual properties within the pharmaceutical sector.



Anders Götzsche
Board member, independent

Mr. Götzsche has been a Board Member of Veloxis since April 2008. Mr. Götzsche is Executive Vice President and Chief Financial Officer at H. Lundbeck.

After finishing his education Anders Götzsche joined PriceWaterhouseCoopers in 1991. From 1998 he was a Sales Manager with the SAS Institute until 2001, after which he became Director of Group Accounting and Reporting in Group 4 Falck. From 2005 he held the post of Chief Financial Officer for the Berlingske Officin. He joined Lundbeck in 2007.

He holds a Master of Science in Accounting from the University of Southern Denmark (1991) and became a state authorized public accountant in 1997.

Special competencies, important for his capacity as a board member of Veloxis, comprise his experience from international and financial management.